These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 12913187)

  • 1. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
    Hauser RA; Hubble JP; Truong DD;
    Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
    Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
    Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
    Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
    J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
    Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
    Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
    Mizuno Y; Hasegawa K; Kondo T; Kuno S; Yamamoto M;
    Mov Disord; 2010 Jul; 25(10):1437-43. PubMed ID: 20629136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
    Mizuno Y; Kondo T;
    Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
    Bara-Jimenez W; Sherzai A; Dimitrova T; Favit A; Bibbiani F; Gillespie M; Morris MJ; Mouradian MM; Chase TN
    Neurology; 2003 Aug; 61(3):293-6. PubMed ID: 12913186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of istradefylline for Parkinson's disease: A meta-analysis.
    Sako W; Murakami N; Motohama K; Izumi Y; Kaji R
    Sci Rep; 2017 Dec; 7(1):18018. PubMed ID: 29269791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
    Chen W; Wang H; Wei H; Gu S; Wei H
    J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
    Wang XL; Feng ST; Chen B; Hu D; Wang ZZ; Zhang Y
    Neurosci Lett; 2022 Mar; 774():136515. PubMed ID: 35149201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease.
    Kondo T; Mizuno Y;
    Clin Neuropharmacol; 2015; 38(2):41-6. PubMed ID: 25768849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
    Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
    BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.